What changed
For most of the past year, the consensus on Mass General Brigham and the point-of-care workflow sat in a place that was easy to ignore. That ended the morning Mass General Brigham began to reshape the point-of-care workflow in production. The clinical informatics stack read it as incremental for about ninety minutes. Then the buyer calls started.
The functional change runs three layers deep: surface (what CMIOs and clinical informatics leads see), interface (what their tools call), and pricing (what the CFO signs). All three moved in the same release. That is rare, and it is the reason the rollout took the market by surprise.
The evidence
Three data points anchor this. First, internal benchmarks from CMIOs and clinical informatics leads who have lived with Mass General Brigham's point-of-care workflow for at least one quarter show time-to-decision compression in the 30–55% band, depending on workload mix. Second, the procurement language has shifted — RFPs that previously named Mass General Brigham as an alternative now name it as the standard. Third, talent flows trail budget flows by one to two quarters; both are moving in the same direction.
The number to internalize is not the time-to-decision delta. It is the time-to-decision delta. CMIOs and clinical informatics leads who would have run a six-week pilot for point-of-care workflow last year are running a six-day pilot now, then signing. Procurement timelines are collapsing in lockstep with deployment timelines, and that compresses the entire revenue cycle for Mass General Brigham and its peers.
Look at the unit economics, not the press releases. The unit economics moved by an order of magnitude.
Second-order effects
There are two reasonable strategic responses. The first is to standardize on Mass General Brigham's approach and redirect engineering effort to the layer above. The second is to wait for the second mover and trade six months of lag for a more mature governance story. Both are defensible. Doing nothing is not.
A more subtle second-order: the regulatory surface. the point-of-care workflow touches data flows that several jurisdictions now actively monitor. Mass General Brigham's default configuration assumes a permissive baseline. CMIOs and clinical informatics leads in regulated environments will need a control plane on top — and a small set of vendors is already positioning to sell exactly that.
What to watch
What we will be watching at the desk between now and the next earnings cycle:
- Sell-side coverage shifts. Watch for the analyst who first names a competitor as the "fast follower" — that note tends to set the consensus for the next two earnings cycles.
- Internal eval framework releases. Mass General Brigham publishing its own benchmark for point-of-care workflow would be a confidence signal. Declining to publish is also a signal, in the other direction.
- Mass General Brigham's next pricing change. Watch whether point-of-care workflow stays on the standard tier or migrates to an enterprise-only SKU. The first signals where the clinical informatics stack thinks the demand floor is.
- Whether the second mover ships a comparable point-of-care workflow primitive within ninety days, or holds back to differentiate on governance. Both are signals, in opposite directions.
Frequently asked
- How does this change procurement for CMIOs and clinical informatics leads in regulated industries?
- The time-to-decision story holds, but the deployment timeline lengthens by one to two quarters because of the control-plane review. Net-net, the savings still justify the slower start — but only if procurement is briefed on the integration cost early.
- What is the most common buyer mistake we see on this?
- Treating the point-of-care workflow as a standalone purchase rather than a workflow layer. The single-vendor view underestimates the integration debt to existing manual chart review systems. Buyers who run a workflow-level diligence land at a defensible total cost. Buyers who run a product-level diligence do not.
- Is there a defensible argument for waiting twelve months?
- In regulated environments and capital-constrained teams, yes. Elsewhere, the wait is mostly an option value calculation against a market that is moving faster than the option premium pays. The math gets worse, not better, with delay.
The next ninety days will tell whether the cohort behavior holds across renewal cycles. We are bullish on the structural read, cautious on the speed of the competitive response, and watching the regulatory posture in one jurisdiction in particular. INTELAR will revisit this story in the next edition.